New research uncovers a cascade of reactions within nerve cells that relay sensations of pain associated with inflammation. The findings, which are published in the British Journal of Pharmacology, indicate that drugs designed to curb this pathway may help relieve inflammatory pain in sufferers.
Previous studies identified that a molecule called Rac1 maintains chronic neuropathic pain resulting from injury to the nervous system. Jun Chen, MD, PhD, of the Fourth Military Medical University in China, and his colleagues wondered if Rac1 might also be involved with chronic inflammatory pain, which is caused by tissue injury, trauma, and diseases such as arthritis. An estimated 20 percent of people worldwide suffer with chronic pain. with the majority of cases being inflammatory pain.
"We found that Rac1 can be activated in chronic inflammatory pain and drugs that curb this reaction can relieve pain, offering the promise of new drugs for pain treatment in the clinic," said Dr. Chen.
These findings were based on experiments involving rats: when investigators injected the paws of rats with bee venom to cause inflammation, Rac1 was activated and set off a cascade of reactions involved in pain perception. In contrast, giving the rodents a molecule that inhibits Rac1 (called NSC23766) before or after the bee venom injection reduced their paw flinches and their pain hypersensitivity.
All studies involving animals were reported in accordance with a set of guidelines referred to as ARRIVE (Animals in Research: Reporting In Vivo Experiments).
Full citation: "Involvement of Rac1 signaling pathway in the development and maintenance of acute inflammatory pain induced by bee venom injection." Yan Wang, Yun-Fei Lu, Chun-Li Li, Wei Sun, Zhen Li, Rui-Rui Wang, Ting He, Fan Yang, Yan Yang, Xiao-Liang Wang, Su-Min Guan, Jun Chen. British Journal of Pharmacology; Published Online: February 10, 2016 (DOI: 10.1111/bph.13413).
URL Upon Publication: http://doi.
Dr. Jun Chen may be reached at firstname.lastname@example.org or +86-29-84777942.
About the Journal
The British Journal of Pharmacology is a broad-based journal giving leading international coverage of all aspects of pharmacology research. Its scope includes all aspects of pharmacology from hypothesis generation and target validation through to model development, safety pharmacology and to early translational research. BJP's 2014 Impact Factor is 4.842, and as such it is a leading general research pharmacology journal (Thomson Reuters Science Citation Index).
About The British Pharmacological Society
The British Pharmacological Society is a charity with a mission to promote and advance the whole spectrum of pharmacology. Founded in 1931, it is now a global community at the heart of pharmacology, with over 3,500 members from more than 60 countries worldwide. The Society leads the way in the research and application of pharmacology around the world through its scientific meetings, educational resources and peer-reviewed journals: the British Journal of Clinical Pharmacology, Pharmacology Research & Perspectives, and the British Journal of Pharmacology, which includes the Concise Guide to PHARMACOLOGY, featuring open access overviews of the key properties of over 1,700 human therapeutic targets and their drugs, and links to http://www.
Press Office: +44 20 7239 0180 | M. +44 7786 552498 | E. email@example.com
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content. The Company's website can be accessed at http://www.